Chia Tai Tianqing

Company snapshot

As the most important subsidiary of Sino Biopharmaceutical Limited, the listed company on the Stock Exchange in Hong Kong under the code 1177, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ) is the top 30 pharmaceutical company in China who expect to be more active in international business with GMP basis approval by EU Health Authority and US FDA, as well as specialized and diversified pr

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Chia Tai Tianqing. Not investment advice.

• What is Chia Tai Tianqing?

  Chia Tai Tianqing is a pharma organization headquartered in CN. Primary therapeutic focus areas include HR-positive, HER2-negative Advanced Breast Cancer, Hyperglycemia. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from publ

• Is Chia Tai Tianqing publicly traded?

  Chia Tai Tianqing appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Chia Tai Tianqing develop or market?

  We link 3 drug profile(s) where Chia Tai Tianqing is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/chia-tai-tianqing-pharmaceutical-group-co#company-drugs.

• What are the latest developments for Chia Tai Tianqing?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Chia Tai Tianqing focus on?

  Chia Tai Tianqing focuses on HR-positive, HER2-negative Advanced Breast Cancer, Hyperglycemia based on our analysis of their pipeline programs and drug development activities.